Who to call at Kairos Pharma, Ltd., and when
Fundz watches for the moments Kairos Pharma, Ltd. starts buying, and tells you who to reach.
- An alert the day Kairos Pharma, Ltd. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kairos Pharma, Ltd., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kairos Pharma, Ltd.. With Fundz connected, it knows.
Kairos Pharma, Ltd.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
AI Executive Summary
AI-powered analysis of 8-K filing content
Kairos Pharma's Compensation Committee granted $950,000 in restricted stock units under its 2023 Equity Incentive Plan to executive officers and independent directors, vesting October 8, 2026, and approved $227,500 in cash bonuses for fiscal 2024 performance. This is a routine compensation action that shows how executive pay is tied to equity and performance.
Key Takeaways
The Compensation Committee approved $950,000 in RSUs on October 8, 2025, priced at $1.31 per share, the Nasdaq closing price on the grant date.
CEO John S. Yu received 190,840 RSUs valued at $250,000, the largest individual equity grant in the filing.
3 more takeaways
Filing Overview
What This Means
Kairos Pharma, Ltd. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.